Benefits
Blood pressure and arterial health
Clinical trials show pomegranate supplementation reduces blood pressure (a modest ~5 mmHg systolic reduction in meta-analysis). A preliminary, unreplicated signal on slowing carotid-artery plaque comes from a single very small trial. Mechanism involves nitric oxide pathway support and reduced vascular oxidative stress.
Endothelial function support
Pomegranate supplementation improves endothelial function and arterial elasticity in adults with cardiovascular risk factors. Effects build over 12+ weeks and support comprehensive cardiovascular health strategies.
Antioxidant capacity
Pomegranate has among the highest antioxidant capacity of common fruits, with documented effects on plasma antioxidant markers. The unique punicalagin profile provides distinct antioxidant activity from other polyphenol sources.
Cognitive aging support (preliminary)
Emerging evidence suggests pomegranate supplementation may support cognitive function in older adults, possibly through urolithin A's mitochondrial effects (see Urolithin A entry). Less robust than the cardiovascular evidence; promising preliminary research.
Cardiometabolic benefits in metabolic syndrome
Trials in adults with metabolic syndrome show pomegranate supplementation modestly improves insulin sensitivity, lipid profiles, and inflammatory markers. Effect sizes consistent with quality cardiovascular polyphenol support.
Punicalagin → urolithin individual variation
Gut bacterial conversion of punicalagin to bioactive urolithins varies between individuals — only roughly 30-40% are 'high urolithin producers.' Those who don't produce urolithin A naturally may benefit more from direct urolithin A supplementation (Mitopure®) than pomegranate extract.
Mechanism of action
Punicalagins and ellagitannin metabolism
Pomegranate punicalagins (~50% of polyphenol content in standardized extracts like Pomella® at ≥30%) are hydrolyzed in the gut to ellagic acid, then converted by Gordonibacter and Eggerthella spp. gut bacteria into urolithins. Urolithin A is the most studied mitophagy-active metabolite. Critical: only ~30-40% of people have the bacterial profile to produce significant urolithin A — direct urolithin supplementation (Mitopure®) bypasses this variability.
Urolithin A and mitophagy
Urolithin A activates mitophagy — the cellular recycling of damaged mitochondria. Mitochondrial dysfunction is causally implicated in muscle aging, sarcopenia, and metabolic decline; direct UA supplementation (Mitopure) has demonstrated muscle strength gains. Direct UA supplementation provides more reliable dosing than relying on gut conversion of pomegranate ellagitannins.
Endothelial NO support and ACE inhibition
Pomegranate polyphenols increase endothelial nitric oxide synthase (eNOS) activity and reduce ACE (angiotensin-converting enzyme) activity. These two mechanisms together explain the consistent BP-lowering effect across meta-analyses. Same pharmacological targets as pharmaceutical antihypertensives (ACE inhibitors, NO donors).
NF-κB inhibition and antioxidant activity
Punicalagins and urolithin A inhibit NF-κB-mediated inflammatory signaling. Direct antioxidant activity (free radical scavenging, lipid peroxidation reduction). Together explain the consistent CRP, IL-6, and oxidized LDL reductions across multiple trials in inflammatory conditions.
Clinical trials
Evidence review and pooled analysis of 8 placebo-controlled clinical trials evaluating pomegranate juice and blood pressure.
2,306 participants
Evidence review and pooled analysis of 8 placebo-controlled clinical trials evaluating pomegranate juice and blood pressure. Pooled effect: SBP -4.96 mmHg (95% CI -7.67 to -2.25, p<0.001), DBP -2.01 mmHg (95% CI -3.71 to -0.31, p=0.021). Effects on SBP remained stable across sensitivity analyses. A subsequent larger meta-analysis (Phytother Res 2024;38:2234-2248) pooling 53 clinical trials confirmed the blood-pressure effect at meta-analytic scale.
Israeli clinical trial in 19 patients with carotid artery stenosis randomized to 50 mL pomegranate juice/day or placebo × up to 3 years.
19 patients with carotid artery stenosis
Israeli clinical trial in 19 patients with carotid artery stenosis randomized to 50 mL pomegranate juice/day or placebo × up to 3 years. Pomegranate group showed ~30% reduction in carotid intima-media thickness vs ~9% increase in placebo. Critical caveat: very small trial (n=19); dramatic IMT effect has not been consistently replicated in larger trials. The 'pomegranate cures atherosclerosis' marketing rests substantially on this small trial.
Open-label single-arm trial in 46 men with rising PSA after prostatectomy or radiation.
46 men with rising PSA after prostatectomy or radiation
Open-label single-arm trial in 46 men with rising PSA after prostatectomy or radiation. 8 oz pomegranate juice/day extended median PSA doubling time from 15 months to 54 months. Critical update: a subsequent randomized, double-blind, placebo-controlled trial (Pantuck 2015) in a similar population was negative — pomegranate extract did not significantly prolong PSA doubling time versus placebo. The uncontrolled single-arm finding has not been independently confirmed. Cancer patients should not replace evidence-based oncology care with pomegranate juice.
Randomized double-blind placebo-controlled trial of Urolithin A (Mitopure®, Amazentis SA) in 88 overweight middle-aged adults. 500 or 1,000 mg/day × 4 months.
88 overweight middle
Randomized double-blind placebo-controlled trial of Urolithin A (Mitopure®, Amazentis SA) in 88 overweight middle-aged adults. 500 or 1,000 mg/day × 4 months. +12% muscle strength vs placebo. Failed primary endpoint of peak power output. Significant secondary improvements in 6-minute walk test and aerobic endurance (peak VO2). Industry-funded; supports the polyphenol → urolithin A → mitophagy mechanism but the magnitude in healthy adults is modest.
Randomized placebo-controlled crossover trial in 53 men with mild-to-moderate erectile dysfunction.
53 men with mild-to-moderate erectile dysfunction
Randomized placebo-controlled crossover trial in 53 men with mild-to-moderate erectile dysfunction. 8 oz/day pomegranate juice × 4 weeks vs placebo. The primary endpoint did not reach statistical significance (P=0.058) — a non-significant trend in this small pilot crossover. Any IIEF-based signal was directional only; the proposed mechanism aligns with the endothelial NO/vascular pathway, but this trial does not establish an erectile-function benefit.